RUNX2 and cardiovascular disorder: In summary, the protein–protein interaction data and our in vivo reporter system has led us to identify FHL2 as a promising candidate for regulating RUNX2 activity in vascular smooth muscles and potential therapeutic target for cardiovascular diseases.